Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Want to see NPCE full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit RNS revenue growth (CFO reported ~20% YoY excluding DIXI), raised full-year guidance, improved adjusted EBITDA outlook, robust clinical data (NAUTILUS 18-month and 3-year focal outcomes), and tangible AI/product roadmap progress. Offsetting risks include the NAUTILUS primary endpoint nuance, IGE revenue timing and payer coverage uncertainty, seasonally lower cash, and ongoing need for reimbursement work. Overall, management presented disciplined investment and operating leverage alongside meaningful opportunities that outweigh near-term risks.Company Guidance
Quarterly Revenue and RNS System Growth
Q1 2026 revenue of $22.1M (or $22.0M excluding DIXI), driven by RNS system revenue of $21.7M. Management highlighted underlying RNS momentum and the CFO reported excluding DIXI non-GAAP revenue of $22.0M, a 20.1% year-over-year increase versus $18.3M in Q1 2025; RNS system revenue grew ~19.5% year-over-year (from $18.2M to $21.7M).
Raised Full-Year 2026 Guidance
NeuroPace raised full-year 2026 revenue guidance to $99M–$101M (up from $98M–$100M). The midpoint increased by ~$1M, driven by improved visibility into service revenue (~$0.5M) and core RNS outlook (~$0.5M); management expects underlying RNS growth of 21%–23% (core adult focal indication) and continues to exclude IGE contribution from guidance.
Improving Adjusted Profitability Metrics
Non-GAAP loss from operations improved to -$3.3M in Q1 2026 versus -$4.1M a year ago; adjusted EBITDA loss improved to -$3.3M (Q1 2026) from -$4.1M (Q1 2025). Full-year adjusted EBITDA outlook improved to a loss of -$8.5M to -$9.5M (previously -$9M to -$10M).
Strong Operating Leverage
Q1 non-GAAP operating expenses were $21.5M versus $19.4M a year ago (~+10%), materially below revenue growth (~20%), demonstrating operating leverage as sales and commercial investments scale.
High Gross Margins and Pricing Tailwind
Q1 non-GAAP gross margin of 82.5% versus 83.6% in the prior year quarter (prior year included a ~120 bps one-time inventory benefit). Management noted underlying gross margin expansion year-over-year driven by favorable pricing conversion and expects full-year adjusted gross margin of 81.5%–82.5%.
Clinical Evidence Strength and Regulatory Progress
Positive NAUTILUS 18-month results presented at AAN: 77% median reduction in generalized tonic-clonic seizures, reductions in absence and myoclonic seizures exceeded GTC reductions, ~30% decline in injury events, and 44% lower benzodiazepine rescue use versus baseline. Company completed FDA mid-cycle (Day 100) meeting for the IGE PMA supplement, responded to follow-up questions promptly, and believes a midyear determination remains on track; breakthrough device designation facilitating interactions.
Published Long-Term Outcomes
3-year post-approval study in drug-resistant focal epilepsy published in Neurology (late April), demonstrating an 82% median seizure reduction, reinforcing long-term durability of RNS outcomes from a prospective FDA-monitored study.
Product and AI Roadmap Progress
ECOG Assistant (AI-enabled seizure identification) showing encouraging internal validation; submission paired with cloud clinician platform migration and expected approval in 2026. Multimodal foundational AI model leveraging >26M intracranial iEEG recordings and ~8,000 patient implants is ~1/3 through training with early internal performance exceeding prior algorithmic approaches.
Commercial and Market Development Momentum
Company reached all-time highs in active prescribers, accounts, and patient pipeline; management reported accelerating additions to the pipeline, continued penetration in Level 4 epilepsy centers, expanding community referral channels, targeted hires and sales incentive changes to improve funnel velocity, and service revenue of $314K from data collaborations.
NPCE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NPCE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $15.80 | $15.81 | +0.06% |
Mar 03, 2026 | $13.83 | $13.95 | +0.87% |
Nov 04, 2025 | $9.40 | $12.98 | +38.09% |
Aug 12, 2025 | $9.13 | $9.32 | +2.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuropace, Inc. (NPCE) report earnings?
Neuropace, Inc. (NPCE) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Neuropace, Inc. (NPCE) earnings time?
Neuropace, Inc. (NPCE) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NPCE EPS forecast?
NPCE EPS forecast for the fiscal quarter 2026 (Q2) is -0.21.